Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma
Authors:
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 89, 107139
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82002872)
- National Natural Science Foundation of China (81402560)
- National Natural Science Foundation of China (81803079)
- National Natural Science Foundation of China (81773110)
- National Natural Science Foundation of China (81572865)
- National Natural Science Foundation of China (81472387)
- Guangdong Provincial Department of Science and Technology (2017A020215029)
- Guangdong Provincial Department of Science and Technology (2014A020212584)
This publication has 40 references indexed in Scilit:
- Recent developments with immunotherapy for hepatocellular carcinomaExpert Opinion on Biological Therapy, 2018
- Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancerCell Death & Disease, 2018
- Immunological landscape and immunotherapy of hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2015
- Immunotherapy for hepatocellular carcinomaDrug Discoveries & Therapeutics, 2015
- Hepatocellular carcinoma epidemiologyBest Practice & Research Clinical Gastroenterology, 2014
- Expression of Annexin A3 in Gastric Cancer and its Correlation with Proliferation and ApoptosisAsian Pacific Journal of Cancer Prevention, 2014
- Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3Hepatology, 2011
- Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patientsJournal of Cellular and Molecular Medicine, 2011
- Hepatocellular Carcinoma: Epidemiology, Surveillance, and DiagnosisSeminars in Liver Disease, 2010
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004